Iqvia (NYSE:IQV) issued its quarterly earnings results on Monday. The medical research company reported $1.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.03, MarketWatch Earnings reports. The firm had revenue of $2.59 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Iqvia updated its FY 2018 guidance to $5.45-5.55 EPS and its FY18 guidance to $5.45-5.55 EPS.
IQV stock opened at $126.89 on Monday. Iqvia has a one year low of $91.57 and a one year high of $132.24. The firm has a market capitalization of $25.71 billion, a PE ratio of 29.10, a PEG ratio of 1.82 and a beta of 0.70. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 1.40.
In other news, Director Ronald A. Rittenmeyer sold 7,680 shares of the firm’s stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $122.41, for a total value of $940,108.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The disclosure for this sale can be found here. Insiders sold a total of 978,777 shares of company stock valued at $121,566,089 in the last 90 days. Company insiders own 6.00% of the company’s stock.
A number of brokerages recently weighed in on IQV. UBS Group began coverage on shares of Iqvia in a research note on Tuesday, October 9th. They set a “buy” rating for the company. Robert W. Baird increased their price target on shares of Iqvia from $143.00 to $146.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 2nd. Raymond James increased their price target on shares of Iqvia from $136.00 to $145.00 and gave the stock a “strong-buy” rating in a research note on Friday, August 31st. Argus set a $136.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research note on Thursday, August 23rd. Finally, Zacks Investment Research cut shares of Iqvia from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $126.95.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Further Reading: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.